Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by Mole101 on Mar 03, 2021 10:08pm

Insider filings

2021-03-0317:20
 
2021-03-01
$ATE Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$8,977 
+1,697 vol 
$5.29 each
8,528  
2021-03-0317:17
 
2021-03-01
$ATE Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
Common Shares
11 - Acquisition or disposition carried out privately
$21,128 
+3,994 vol 
$5.29 each
11,525  
2021-03-0317:13
 
2021-03-01
$ATE Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Holder: Schmed Enterprises Inc. (Control or Direction)
Common Shares
11 - Acquisition or disposition carried out privately
$116,210 
+21,968vol 
$5.29 each
72,096  
2021-03-0317:12
 
2021-03-01
$ATE Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$457,987 
+86,576vol 
$5.29 each
204,714  
2021-03-0317:08
 
2021-03-01
$ATE Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$765,775 
+144,759vol 
$5.29 each
314,416  
2021-03-0317:07
 
2021-03-01
$ATE Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Holder: AltaPharm International Inc. (Control or Direction)
Common Shares
11 - Acquisition or disposition carried out privately
Comment by Miso420 on Mar 03, 2021 10:27pm
Whoa these were all today ? 
Comment by Pragmatist on Mar 03, 2021 11:42pm
Once again Mole..  Well ahead of the crowd with your posts.  Well done!  Do you have any thoughts on the common transaction price?
Comment by Doccole on Mar 04, 2021 5:40am
Lol Prag CEO.ca files these documents, real easy to see. knowing the Hx of Dan the Momentum Crusher! I'll wait for his big sell of after some type of news.  Ironic in that he complained about retail selling the news after phase 2 results, and he sold a bunch. either way, should move up eventually.  The team seems solid.  I say deal with big pharma by September. 
Comment by Doccole on Mar 04, 2021 6:26am
Question about the filings- Under totals for Dan and John, the balance keeps going up, and then down. The total says current units. Are they selling the heck out of new shares? Keeps showing privately carried out but their totals are lower, thoughts?
Comment by Pragmatist on Mar 04, 2021 2:23pm
I think that SEDI reports, as separate numbers:   1.  shares that are owned directly by insiders; and   2. shares  which the insiders direct or control (e.g. Elegen, Altapharm and Schmed).   This would explain the variance in numbers.   When Antibe was first incorporated, I believe that Legault/Wallace performed their duties under personal services ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities